Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A thymic peptide that plays a central role in immune system regulation. Approved as a drug in over 35 countries (though not in the US) for hepatitis B and C treatment and as an immune booster.
A tripeptide (Lysine-Proline-Valine) derived from the C-terminus of alpha-MSH (melanocyte-stimulating hormone). Has potent anti-inflammatory properties and is being studied for inflammatory bowel conditions and wound healing.
Enhances T-cell function, promotes dendritic cell maturation, and modulates cytokine production. Acts as an immune system regulator rather than a simple stimulant, helping to balance immune responses.
Inhibits NF-κB signaling and pro-inflammatory cytokine production. Crosses the intestinal epithelium to directly suppress inflammation locally. Anti-microbial properties have also been demonstrated in vitro.
- Immune system support
- Chronic infection management
- Cancer adjunct therapy (in some countries)
- Post-illness recovery
- Autoimmune condition management
- Inflammatory bowel disease (IBD) support
- Wound healing and skin conditions
- General anti-inflammatory protocols
- Gut health optimization
- Generally well-tolerated in clinical use
- Injection site reactions
- Rare allergic reactions
- May interact with immunosuppressive drugs
- Very limited human clinical data
- Optimal delivery method not established
- Injection vs. oral bioavailability differences not fully characterized
- Long-term safety unknown
Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Approved as Zadaxin in 35+ countries but not FDA-approved in the US. Available through licensed 503A compounding pharmacies with a physician prescription.
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 23, 2026 for wound healing and inflammatory conditions. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
PCAC: July 23, 2026
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.